Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 120566292 | 12056629 | 2 | F | 201508 | 20160720 | 20160210 | 20160726 | EXP | CA-AMGEN-CANSL2016013379 | AMGEN | 63.00 | YR | A | F | Y | 64.40000 | KG | 20160726 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 120566292 | 12056629 | 1 | PS | PROLIA | DENOSUMAB | 1 | Subcutaneous | 60 MG/ML, Q6MO | U | 1055509 | 125320 | SOLUTION FOR INJECTION | |||||||
| 120566292 | 12056629 | 2 | SS | CALCIUM | CALCIUM | 1 | Unknown | 0 | |||||||||||
| 120566292 | 12056629 | 3 | C | TYLENOL | ACETAMINOPHEN | 1 | 0 | ||||||||||||
| 120566292 | 12056629 | 4 | C | NYSTATIN. | NYSTATIN | 1 | 5 ML, BID | 0 | 5 | ML | BID | ||||||||
| 120566292 | 12056629 | 5 | C | QUININE SULFATE. | QUININE SULFATE | 1 | 300 MG, QD | 0 | 300 | MG | QD | ||||||||
| 120566292 | 12056629 | 6 | C | VITAMIN D | CHOLECALCIFEROL | 1 | 1000 UNK, QD | 0 | QD | ||||||||||
| 120566292 | 12056629 | 7 | C | AVAMYS | FLUTICASONE FUROATE | 1 | 27.5 MUG, 2 SPRAYS 1 TIME DAILY | 0 | 27.5 | UG | |||||||||
| 120566292 | 12056629 | 8 | C | VIMOVO | ESOMEPRAZOLE MAGNESIUMNAPROXEN | 1 | 500-20 MG, BID | 0 | BID | ||||||||||
| 120566292 | 12056629 | 9 | C | CLOTRIMAZOLE. | CLOTRIMAZOLE | 1 | 1 %, BID | 0 | 1 | PCT | BID | ||||||||
| 120566292 | 12056629 | 10 | C | VAGIFEM | ESTRADIOL | 1 | 10 MUG, QD | 0 | 10 | UG | QD | ||||||||
| 120566292 | 12056629 | 11 | C | KETOCONAZOLE. | KETOCONAZOLE | 1 | 2 %, BID | 0 | 2 | PCT | BID | ||||||||
| 120566292 | 12056629 | 12 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | 20 MG, QD | 0 | 20 | MG | QD | ||||||||
| 120566292 | 12056629 | 13 | C | CETIRIZINE | CETIRIZINE HYDROCHLORIDE | 1 | 20 MG, QD | 0 | 20 | MG | QD | ||||||||
| 120566292 | 12056629 | 14 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | 500 MG, BID | 0 | 500 | MG | BID | ||||||||
| 120566292 | 12056629 | 15 | C | VAXIGRIP | INFLUENZA VIRUS VACCINE | 1 | UNK | 0 | |||||||||||
| 120566292 | 12056629 | 16 | C | ZOSTAVAX II | 2 | UNK | 0 | ||||||||||||
| 120566292 | 12056629 | 17 | C | MAGNESIUM | MAGNESIUM | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 120566292 | 12056629 | 1 | Osteoporosis |
| 120566292 | 12056629 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 120566292 | 12056629 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 120566292 | 12056629 | Aphthous ulcer | |
| 120566292 | 12056629 | Arthralgia | |
| 120566292 | 12056629 | Constipation | |
| 120566292 | 12056629 | Muscle spasms | |
| 120566292 | 12056629 | Nephrolithiasis | |
| 120566292 | 12056629 | Oral herpes | |
| 120566292 | 12056629 | Oral pain | |
| 120566292 | 12056629 | Pain in extremity | |
| 120566292 | 12056629 | Tenderness | |
| 120566292 | 12056629 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 120566292 | 12056629 | 1 | 201502 | 0 | ||
| 120566292 | 12056629 | 15 | 20141027 | 0 | ||
| 120566292 | 12056629 | 16 | 20160201 | 0 |